Why did revenue fall faster in the third quarter?

  • Zai Lab’s total revenue in 3Q26 was US$108.2 million, down 7% year over year and up 2% quarter over quarter; the year-over-year decline widened from 3% in 2Q26. Revenue was also about 4% below Bernstein’s expectation of US$113 million.
  • Two major products continued to weigh on revenue: Zejula revenue was US$32 million, down 24% year over year amid generic competition; Vyvgart revenue was US$24 million, down 13% amid NRDL price cuts and intensifying competition in the myasthenia gravis market. Together, the two accounted for about half of revenue.
  • Growth in some newer products provided a buffer: Nuzyra revenue was US$21 million, up 37% year over year and 23% quarter over quarter; KarXT, launched in June, also contributed revenue. The growth was not enough to offset the decline in major products.

Did the narrower loss reflect stronger operations or lower expenses?

  • The operating loss in 3Q26 was US$63 million, narrowing 18% from US$76 million in 2Q26; the operating margin improved from -72% in the prior quarter to -58%.
  • R&D expenses fell from US$62 million in 2Q26 to US$50 million, a quarter-over-quarter decline of 19%, and were an important reason for the narrower loss. At the same time, Optune revenue was only US$8 million, down 38% year over year and 36% quarter over quarter, indicating continued significant pressure on the product side; the improvement in the loss was not driven by revenue growth.

Which better represents the institution’s view: flat revenue in 2026 or the revenue forecast table?

  • Bernstein said that broadly flat revenue in 2026 could be expected; its view of a recovery in 2027 depends on higher use of Vyvgart’s subcutaneous formulation and KarXT under potential NRDL coverage, a recovery in Zejula sales, the easing of Xacduro supply constraints, and plans for local production in 2027.
  • However, the report’s financial table lists revenue forecasts of 2025A: US$460.16 million, 2026E: US$496.43 million, and 2027E: US$595.33 million. Based on the figures in the table, revenue in 2026 is up about 8% from 2025, which does not align with the written description of being “flat”; the model’s revenue for 2027 is up about 20% from 2026.

Can the pipeline make up for weak near-term growth? How does Bernstein value the stock?

  • Zoci reported a confirmed objective response rate of 81.8% in a first-line small-cell lung cancer study, with an estimated six-month progression-free survival rate of 81.9% and an incidence of related adverse events of grade 3 or higher of 9.1%. Bernstein said these data support advancing a global Phase III first-line study and expects a potential BLA filing in 2027; however, the firm also noted that near-term growth still lacks strong support, while Zoci remains an important potential re-rating driver for the portfolio.
  • Bernstein maintained its Market-Perform rating and a target price of 15 Hong Kong dollars; relative to the closing price of 18.01 Hong Kong dollars on 4 November 2026, this implies downside of about 17%. The target price is based on a valuation methodology combining DCF and a two-year forward price-to-sales ratio.

Related topics